Category icon
ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall

Category icon
Inflammation and Cardiovascular Disease: The Future

Natalie Arnold, Katharina Lechner, Christoph Waldeyer, et al

Category icon
Rheumatoid Arthritis and Atherosclerotic Cardiovascular Disease

Anne Mirjam Kerola, Silvia Rollefstad, Anne Grete Semb,

Category icon
Dyslipidaemia in the Real World

Ricardo Lopez Santi, Felipe Martínez, Adrian Baranchuk, et al

Category icon
Bridging the Gap in a Rare Cause of Angina

Sumanth Khadke, Jovana Vidovic, Vinod Patel,

Category icon
Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg W Stone, et al

Category icon
Statins and Insulin Resistance

GM Sanvee, M Panajatovic, J Bouitbir, et al

About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Related Articles

Articles

Inflammation and Cardiovascular Disease: The Future

Natalie Arnold, Katharina Lechner, Christoph Waldeyer,

Published:

Citation: European Cardiology Review 2021;16:e20.

The Association Between Psoriasis and Cardiovascular Diseases

Ahmed Zwain, Mohanad Aldiwani, Hussein Taqi,

Published:

Citation: European Cardiology Review 2021;16:e19.

Rheumatoid Arthritis and Atherosclerotic Cardiovascular Disease

Anne Mirjam Kerola, Silvia Rollefstad, Anne Grete Semb,

Published:

Citation: European Cardiology Review 2021;16:e18.

Dyslipidaemia in the Real World

Ricardo Lopez Santi, Felipe Martínez, Adrian Baranchuk,

Published:

Citation: European Cardiology Review 2021;16:e16.